Immune checkpoint inhibitors (ICIs) are rapidly developing immunotherapy cancer drugs that have prolonged patient survival. However, ICIs-related cardiotoxicity has been recognized as a rare, but fatal, consequence. Although there has been extensive research based on different types of ICIs, these studies have not indicated whether cardiotoxicity is specific to a type of cancer. Therefore, we conducted a systematic review to analyze a variety of ICIs-related cardiotoxicity, focusing on different types of cancer. We found that the incidence of ICIs-related cardiac adverse events (CAEs) and common cardiotoxic manifestations vary with cancer type. This inspired us to explore the underlying mechanisms to formulate targeted clinical strategies for maintaining the cardiovascular health of cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324462 | PMC |
| http://dx.doi.org/10.3390/jcdd9070203 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study of stress-strain loops on cardiotoxicity related to immune checkpoint inhibitors.
Echocardiography
January 2024
Department of Diagnostic and Therapeutic Ultrasonography, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Article Synopsis
- The study aimed to assess how immune checkpoint inhibitors (ICIs) impact left ventricular myocardial work using pressure-strain loops (PSL) in heart function.
- Involvement included 43 patients receiving immunotherapy and 43 healthy controls, with measurements taken at three different treatment phases (before, after three cycles, and after six cycles).
- Results showed a significant decline in specific myocardial work indices after treatment, indicating potential cardiotoxic effects from ICIs, while conventional echocardiographic parameters remained unchanged.
Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work.
Quant Imaging Med Surg
May 2023
Department of Ultrasound, the Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background: The treatment of advanced lung cancer has been revolutionized by immune checkpoint inhibitors (ICIs) in recent years, largely driven by programmed cell death-1 (PD-1) inhibitors. However, patients with lung cancer who are treated with PD-1 inhibitors are prone to immune-related adverse events (irAEs), especially cardiac adverse events. Noninvasive myocardial work is a novel technique used to assess left ventricular (LV) function, which can effectively predict myocardial damage.
View Article and Find Full Text PDFPD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS).
Expert Opin Drug Saf
February 2024
Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, China.
Background: Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors have reformed the treatment landscape for various malignancies and improved prognosis of patients. However, they also lead to events that although rare may prove to be fatal.
Research Design And Methods: Data from July 2014 to June 2022 based on FDA Adverse Event Reporting System (FAERS) were analyzed.
ICIs-Related Cardiotoxicity in Different Types of Cancer.
J Cardiovasc Dev Dis
June 2022
Department of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, China.
Immune checkpoint inhibitors (ICIs) are rapidly developing immunotherapy cancer drugs that have prolonged patient survival. However, ICIs-related cardiotoxicity has been recognized as a rare, but fatal, consequence. Although there has been extensive research based on different types of ICIs, these studies have not indicated whether cardiotoxicity is specific to a type of cancer.
View Article and Find Full Text PDF[Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Zhongguo Fei Ai Za Zhi
September 2021
Department of Oncology, The Second Affiliated Hospital of Nanchang University, Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang 330006, China.
Immune checkpoint inhibitors (ICIs) is a negative regulatory factor antibody, which activates T cells to play an anti-tumor effect in immunotherapy, and can also cause immune-related adverse responses, thereby inducing a series of immune related adverse events (irAEs). Among these irAEs, although the incidence of ICIs-related myocarditis is very low, the fatality rate is significantly higher than other adverse reactions, close to 50%. Clinicians should be vigilant when applying ICIs, but the pathogenesis of ICIs-related myocarditis is still unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!